La Jolla Pharmaceuticals Company
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 2, 2007
La Jolla Pharmaceutical Company
 
(Exact name of registrant as specified in its charter)
         
Delaware   0-24274   33-0361285
         
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (IRS Employer
Identification No.)
     
6455 Nancy Ridge Drive, San Diego, California   92121
     
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: (858) 452-6600
N/A
 
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

2.02 Results of Operations and Financial Condition.
9.01 Financial Statements and Exhibits.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1

Table of Contents

2.02 Results of Operations and Financial Condition.
     On August 2, 2007, La Jolla Pharmaceutical Company announced and commented on its second quarter and year-to-date financial results for the periods ended June 30, 2007. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
     The information in this Form 8-K and the exhibit attached hereto and incorporated by reference herein shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibit is furnished with this report on Form 8-K:
     
Exhibit    
Number   Description of Exhibit
 
    
99.1
  Press Release (furnished pursuant to Item 2.02 of Form 8-K)

 

Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  La Jolla Pharmaceutical Company
 		  
Date: August 2, 2007  By:   /s/ Gail A. Sloan    
    Gail A. Sloan   
    Vice President of Finance and Secretary
(Principal Accounting Officer) 		  

 

Table of Contents

         
EXHIBIT INDEX
     
Exhibit    
Number   Description of Exhibit
 
    
99.1
  Press Release (furnished pursuant to Item 2.02 of Form 8-K)